Last quarter (Q ), CytoDyn's total revenue was $―, a decrease of ― from the same quarter last year. In Q, CytoDyn's net income was $-11.92M. See CytoDyn’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	May 23	May 22	May 21	May 20	May 19
Total Revenue	-	-	$ 300.00K	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	$ 20.63M	$ -53.00K	-	-	-
Gross Profit	-	$ -20.63M	$ 213.00K	-	-	-
Operating Expense	$ 26.83M	$ 31.82M	$ 75.17M	$ 94.55M	$ 74.65M	$ 55.85M
Operating Income	$ -25.30M	$ -40.58M	$ -148.43M	$ -94.55M	$ -74.65M	$ -55.85M
Net Non Operating Interest Income Expense	$ -14.13M	$ -22.75M	$ -50.26M	$ -19.55M	$ -18.21M	$ -3.31M
Other Income Expense	$ 6.20M	-	$ 6.69M	$ -40.57M	$ -31.54M	$ 146.87K
Pretax Income	$ -51.69M	$ -79.82M	$ -210.82M	$ -154.67M	$ -124.40M	$ -59.01M
Tax Provision	-	-	-	$ 0.00	$ 0.00	$ -2.83M
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -51.69M	$ -79.82M	$ -210.80M	$ -154.67M	$ -124.40M	$ -56.19M
Basic EPS	$ -0.05	$ -0.10	$ -0.31	$ -0.27	$ -0.30	$ -0.21
Diluted EPS	$ -0.05	$ -0.10	$ -0.31	$ -0.27	$ -0.30	$ -0.21
Basic Average Shares	$ 3.70B	$ 836.53M	$ 676.90M	$ 587.59M	$ 421.08M	$ 272.04M
Diluted Average Shares	$ 3.70B	$ 836.53M	$ 676.90M	$ 587.59M	$ 421.08M	$ 272.04M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 26.83M	$ 52.45M	$ 75.22M	$ 94.55M	$ 74.65M	$ 55.85M
Net Income From Continuing And Discontinued Operation	$ -51.69M	$ -79.82M	$ -210.80M	$ -154.67M	$ -124.40M	$ -56.19M
Normalized Income	$ -43.15M	-	-	$ -114.10M	$ -92.36M	$ -56.33M
Interest Expense	-	-	-	$ 19.34M	$ 16.88M	$ 2.85M
EBIT	$ -13.70M	$ -52.45M	$ -160.56M	$ -135.33M	$ -107.52M	$ -56.16M
EBITDA	$ -2.04M	$ -40.40M	$ -156.73M	$ -133.53M	$ -105.49M	$ -54.91M

Currency in USD

CytoDyn Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing